Mitomycin, doxorubicin, and vinblastine as second-line chemotherapy in patients with advanced breast cancer

Thirty-seven patients with disseminated breast cancer refractory to previous therapy were treated with a combination of mitomycin, doxorubicin, and vinblastine (MAV). One complete and eight partial responses were achieved, with an overall response rate of 24.3%. The median duration of response was 5+ months. The MAV regimen had generally moderate but acceptable toxicity. This study indicates that the MAV combination is no better than doxorubicin given as a single agent.